
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem Inc. is exhibiting a positive outlook due to its innovative pipeline of anticancer agents, particularly with the promising performance of VS-7375 in the competitive KRAS G12D landscape, where it is considered a best-in-class candidate. The drug has garnered strong enthusiasm among physicians and is experiencing better response rates, with low discontinuation rates compared to historical MEK inhibitors, indicating potential for substantial growth. Additionally, the observed effectiveness in both KRAS mutant and wild-type tumors, along with the ability for patients to remain on treatment, supports broader clinical adoption and a favorable market position.
Bears say
Verastem Inc. has experienced continuous operating losses since its inception, raising concerns about its ability to achieve profitability in the foreseeable future. The challenges associated with KRAS inhibition, particularly in colon cancer, are highlighted by lower overall response rates and weaker responses to treatments in patients with specific KRAS mutations compared to others. Furthermore, delays in regulatory approval processes could adversely affect the company's prospects and lead to further negative sentiment surrounding its stock performance.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares